12 - 15 November 2015 Barcelona, Spain
6-P | The 4Kscore test predicts upgrading at prostatectomy among men with low-grade prostate cancer on prostate biopsy | Alberto Briganti | Received |
14-P | External radiation-therapy versus brachytherapy in low risk prostate cancer. RECAP-database analysis | Gustavo Ossola Lentati | Received |
24-P | Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients treated with radical prostatectomy | Arnau Serra Deola | Received |
25-P | Prospective evaluation on the outcome of inclusion of a multiparamentric MRI scan In MRI nave patients with low risk prostate cancer, already established on active surveillance | Thiru Suntharasivam | Received |
30-P | Erectile dysfunction a post-open radical prostatectomy. Prospective analysis of results. | Virginia Del Rosario Rodríguez | Received |
43-P | Accuracy of kallikrein testing (4K) in prostate cancer detection and grading. A preliminary prospective study | Francisco Clar | Received |
46-P | A Phase 3 study of enzalutamide in non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) patients | Heather Sylvestro | Received |
47-P | Penile metastasis: A rare presentation of prostate cancer | Pedro Oliveira | Received |
52-P | Efficacy of abiraterone acetate in chemotherapy-naive patients with mCRPC presenting with visceral disease | Marina Mencinger | Received |
54-P | Survival after biochemical failure in prostate cancer: Recap database outcomes | Carmen González-San Segundo | Received |
60-P | How bad is the outcome of node positive prostate cancer patients: A matched case analysis between N and N0 prostate cancer patients | Valérie Fonteyne | Received |
78-P | Variation in prescription rate of the first post-docetaxel treatment and overall survival among patients with mCPRC in the CAstration-resistant Prostate cancer RegIstry (CAPRI): An observational study in the Netherlands | Hans Westgeest | Received |
84-P | Docetaxel treatment in castration-resistant prostate cancer (CRPC) clinical trials compared to standard care: Treatment duration and overall survival (OS) in CAPRI: An observational study in the Netherlands | Hans Westgeest | Received |
86-P | An audit and indirect comparison of the use of Cabazitaxel (CBZ) for the treatment of metastatic Castrate Resistant Prostate Cancer (mCRPC) progressing after docetaxel compared to previous experience with ECarboF | Mark Linch | Received |
95-P | Preferences for the management of androgen deprivation-induced osteoporosis and metabolic syndrome in prostate cancer patients: A European web-based survey | Piet Ost | Received |
96-P | Standard practice compared to evidence based strategies for the management of androgen deprivation-induced side effects in prostate cancer patients: A European web-based survey | Piet Ost | Received |
98-P | Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumour recurrence | Koji Izumi | Received |
104-P | Urothelial bladder pTx tumours. How to predict positivity of the immediate second TUR | Ignacio Arroyo Soto | Received |
108-P | Urinary exosomes: Promising biomarkers for urothelial bladder cancer | Renan Javier Otta Oshiro | Received |
122-P | A comparison of the efficacy of neoadjuvant versus adjuvant chemotherapy in the treatment of locally advanced bladder cancer | Tanja Ovcaricek | Received |
145-P | Ex vivo MRI as a tool to assess surgical margins directly following partial nephrectomy. | Tim van Oostenbrugge | Received |
149-P | Ablative treatment for small renal solid masses through cryotherapy and radiofrecuency: Efficacy and safety | DAVID CARRACEDO | Received |
153-P | Outcomes of conservative treatment of upper urinary tract carcinoma after a long term follow-up | Andrea Orosa Andrada | Received |
159-P | Small lung nodules at diagnosis should not automatically be considered metastatic renal cancer | Philippa Jefferson | Received |
12 - 15 November 2015 Barcelona, Spain
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|